{"id":"NCT00620061","sponsor":"Sucampo Pharma Americas, LLC","briefTitle":"Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone","officialTitle":"A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2009-09","completion":"2009-09","firstPosted":"2008-02-21","resultsPosted":"2019-12-30","lastUpdate":"2020-01-21"},"enrollment":439,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Opioid-Induced Bowel Dysfunction"],"interventions":[{"type":"DRUG","name":"Lubiprostone 24","otherNames":["Amitiza"]}],"arms":[{"label":"All Participants","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in participants with opioid-induced bowel dysfunction.","primaryOutcome":{"measure":"Mean Weekly Spontaneous Bowel Movements (SBMs) Per Month","timeFrame":"Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9","effectByArm":[{"arm":"All Participants","deltaMin":1.4,"sd":0.98}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":123,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":439},"commonTop":["Diarrhoea","Nausea","Upper Respiratory Tract Infection","Back Pain"]}}